210 related articles for article (PubMed ID: 16198056)
1. The future of fulvestrant ("Faslodex").
Howell A
Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Howell A
Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of fulvestrant ("Faslodex").
Howell A; Abram P
Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant (Faslodex) -- how to make a good drug better.
Robertson JF
Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
[TBL] [Abstract][Full Text] [Related]
9. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
[TBL] [Abstract][Full Text] [Related]
10. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
13. Pure oestrogen antagonists for the treatment of advanced breast cancer.
Howell A
Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
[TBL] [Abstract][Full Text] [Related]
14. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Abram P; Maass N; Rea D; Simon SD; Steger GG
Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L
Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057
[TBL] [Abstract][Full Text] [Related]
18. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Chia S; Gradishar W
Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Dodwell D; Wardley A; Johnston S
Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]